Overview

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)

Status:
Completed
Trial end date:
2021-01-25
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to investigate the safety and tolerability of BGB-DXP593 administered intravenously as a single dose in participants with mild-to-moderate COVID-19.
Phase:
Phase 2
Details
Lead Sponsor:
BeiGene